Intensity Therapeutics' INT230-6 Demonstrates Increased Survival As Either Monotherapy Or In Combination With Pembrolizumab In Patients With Relapsed, Refractory, Metastatic Solid Tumor Cancers
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival As Either Monotherapy Or In Combination With Pembrolizumab In Patients With Relapsed, Refractory, Metastatic Solid Tumor Cancers
Intensity Therapeutics 的 INT230-6 表明,无论是单一疗法还是与 pembrolizumab 联合使用,复发、难治性、转移性实体瘤患者的存活率都有所提高
Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 Days
单独接受 INT230-6(n=64)的患者的总存活率中位数(mOS)为 373 天
Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors
数据显示 INT230-6 耐受性良好,在各种实体瘤中既能直接杀灭肿瘤,又能产生免疫激活作用
Combined with Pembrolizumab in a Population Consisting of Heavily Pretreated Patients with Primarily Pancreatic, Bile Duct, Colorectal, and Triple Negative Breast Cancer (n=24), Whose Cancer Progressed, the mOS was 205 Days
在主要患有胰腺癌、胆管癌、结直肠癌和三阴性乳腺癌(n=24)、癌症进展的患者群体中,与Pembrolizumab 联合使用,mOS 为 205 天
Full Set of Results to be Presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
全套结果将在2022年癌症免疫疗法学会(SITC)年会上公布